Citadel Advisors’s Revelation Biosciences REVB Stock Holding History

Citadel Advisors’s Portfolio REVB Stock Details REVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.7K	Buy	+38,579	New	+$41.9K	﹤0.01%	13227
2026 Q1	–	Sell	-13,682	Closed	-$43.8K	–	14025
2025 Q4	$43.8K	Buy	+13,682	New	+$59.9K	﹤0.01%	12094
2024 Q1	–	Sell	-4	Closed	-$12.1K	–	15325
2023 Q4	$12.1K	Sell	4 -6	-60%	-$21.4K	﹤0.01%	13009
2023 Q3	$39K	Buy	+10	New	+$44.1K	﹤0.01%	12021
2022 Q4	–	Hold	0	–	-$6K	–	15355
2022 Q3	–	Hold	0	–	–	–	12350
2022 Q2	–	Hold	0	–	-$49K	–	13903
2022 Q1	–	Hold	0	–	–	–	12800

Other funds holding REVB

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Citadel Advisors's REVB Position: Q2 2026 in Review

Citadel Advisors opened a new position in Revelation Biosciences (REVB) in Q2 2026: 38,579 shares worth $39.7K. The stake represents ﹤0.01% of the portfolio and ranks #13227 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in REVB as recently as Q4 2025.

Citadel Advisors first reported a position in REVB in Q3 2023 and has held it in 4 quarters since. The position peaked at $43.8K in Q4 2025. 12 funds tracked by Wall St. Rank hold REVB as of Q2 2026.

Citadel Advisors held 38,579 shares of Revelation Biosciences worth $39.7K as of Q2 2026.
Revelation Biosciences was a new Citadel Advisors position in Q2 2026.
Revelation Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13227 holding.
Citadel Advisors first reported a position in Revelation Biosciences in Q3 2023 and has held it in 4 quarters since.
Citadel Advisors's Revelation Biosciences position peaked at $43.8K in Q4 2025.
12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.